Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3370216 | 0.81 | BACE1 (0.46) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL15643469 | 0.80 | LMNA (1.00) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL25260780 | 0.73 | SMN1; SMN2 (0.53) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL25253430 | 0.73 | MAPT (0.59) | LMNAKDM4EALDH1A1CA1CA2 | |
| SCHEMBL14360705 | 0.73 | MAPT (0.50) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29589106 | 0.72 | MAPT (0.57) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2573157 | 0.71 | ALDH1A1 (0.53) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6498233 | 0.71 | KDM4E (0.49) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1494699 | 0.70 | ALDH1A1 (0.55) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2730926 | 0.70 | PHGDH (0.59) | LMNAKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | LMNA 3914/4885KDM4E 718/4885ALDH1A1 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.